Shilpa Medicare has informed that the company’s 100% subsidiary, Shilpa Pharma Lifesciences received certificate of suitability (CEP) from EDQM (European Directorate for the Quality of Medicines & Healthcare) for API, Teriflunomide.
The above information is a part of company’s filings submitted to BSE.